Detalhe da pesquisa
1.
Soluble Guanylyl Cyclase Activator BI 685509 Reduces Portal Hypertension and Portosystemic Shunting in a Rat Thioacetamide-Induced Cirrhosis Model.
J Pharmacol Exp Ther
; 386(1): 70-79, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37230799
2.
The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease.
J Pharmacol Exp Ther
; 384(3): 382-392, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507845
3.
G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanism.
J Pharmacol Exp Ther
; 348(3): 421-31, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24399854
4.
Strategic integration of in vivo cardiovascular models during lead optimization: predictive value of 4 models independent of species, route of administration, and influence of anesthesia.
J Cardiovasc Pharmacol
; 59(4): 369-76, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22179024
5.
Cardiovascular safety pharmacology studies in dogs enabled for a poorly soluble molecule using spray-dried dispersion: Impact on lead selection.
Int J Pharm
; 512(1): 137-146, 2016 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27543349
6.
Long-term stability, reproducibility, and statistical sensitivity of a telemetry-instrumented dog model: A 27-month longitudinal assessment.
J Pharmacol Toxicol Methods
; 74: 26-32, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25946685
7.
New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.
Bioorg Med Chem Lett
; 14(2): 549-52, 2004 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-14698201